Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM

Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM

Objective: an assessment of efficacy and safety of lenvatinib in combination with everolimus in unselected patients with metastatic renal cell carcinoma (mRCC) progressed during or following ≥1 line of antiangiogenic targeted therapy.Material. Russian multicenter observational study ROSLERCM include...

Full description

Bibliographic Details
Main Authors: M. I. Volkova, A. M. Abdelgafur, M. T. Aivazov, Z. V. Amoev, K. G. Babina, P. S. Borisov, A. A. Vorontsovа, I. V. Evstigneeva, O. I. Evsyukova, O. V. Zhelezin, A. S. Kalpinsky, E. V. Karabina, N. V. Kirdakova, G. P. Kolesnikov, E. S. Kuzmina, D. Kh. Latipova, R. V. Leonenkov, M. R. Maturov, A. V. Meskikh, S. V. Mishugin, E. G. Ovchinnikova, A. S. Olshanskaya, S. A. Protsenko, T. Yu. Semiglazova, R. V. Smirnov, E. A. Usynin, M. M. Fael, E. M. Cherniakova, I. E. Shumskaya
Format: Article
Language:Russian
Published: ABV-press 2019-10-01
Series:Onkourologiâ
Subjects:
lenvatinib in combination with everolimus
metastatic renal cell carcinoma
2nd line therapy
Online Access:https://oncourology.abvpress.ru/oncur/article/view/984

Internet

https://oncourology.abvpress.ru/oncur/article/view/984

Similar Items